This company is no longer active
Humanigen Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Cameron Durrant
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 8.3yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$54m |
| Dec 31 2022 | US$1m | US$640k | -US$71m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$152m |
| Mar 31 2022 | n/a | n/a | -US$192m |
| Dec 31 2021 | US$10m | US$640k | -US$237m |
| Sep 30 2021 | n/a | n/a | -US$235m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$153m |
| Dec 31 2020 | US$2m | US$600k | -US$90m |
| Sep 30 2020 | n/a | n/a | -US$59m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | US$785k | US$600k | -US$10m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$9m |
| Dec 31 2018 | US$4m | US$600k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$13m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$22m |
| Dec 31 2017 | US$790k | US$600k | -US$22m |
Compensation vs Market: Insufficient data to establish whether Cameron's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Cameron's compensation has been consistent with company performance over the past year.
CEO
Cameron Durrant (64 yo)
8.3yrs
Tenure
US$1,099,058
Compensation
Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, FLSW, has been Chairman of Humanigen, Inc. since January 2016. Dr. Durrant has been Chief Executive Officer at Humanigen, Inc. since March 2016 and has be...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.5yrs | US$1.10m | no data | |
| Chief Scientific Officer & Director | 3.4yrs | US$661.96k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$81.20k | 0.071% $ 0.08 | |
| Independent Director | 8.5yrs | US$61.60k | 0.075% $ 0.09 |
7.5yrs
Average Tenure
64yo
Average Age
Experienced Board: HGEN.Q's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/15 14:49 |
| End of Day Share Price | 2024/07/15 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Humanigen, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cosme Ordoñez | B. Riley Wealth |
| Olga Smolentseva | Bryan Garnier & Co |
| Louise Chen | Cantor Fitzgerald & Co. |